Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility

The U.S. FDA inspected Lupin's manufacturing facility at Aurangabad from March 6 to March 15, 2024. The inspection closed with the issuance of a Form-483 with one (1) observation.

The company is confident of addressing the concern raised by the U.S. FDA and will resolve the same at the earliest. We uphold quality and compliance with utmost importance and are committed to comply with CGMP quality standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 1639.65 as compared to the previous close of Rs. 1649.50. The total number of shares traded during the day was 13602 in over 1965 trades.

The stock hit an intraday high of Rs. 1660.10 and intraday low of 1613.40. The net turnover during the day was Rs. 22169351.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Form483 1Observation USFDA